**RADBOUD BIOBANK REVIEW FORM**

|  |  |
| --- | --- |
| Radboud Biobank | **QUESTIONS?**Peggy Manders, Radboud BiobankRadboudumc (830), P.O. Box 9101, 6500 HB NijmegenEmail: peggy.manders@radboudumc.nl Tel: +31-24-3668977 |

**NB**: Please check our policy for the review of requests for samples from a approved sub-biobank. To find out if CMO Radboudumc approval is necessary for your request please visit the [CMO website](https://www.radboudumc.nl/over-het-radboudumc/kwaliteit-en-veiligheid/commissie-mensgebonden-onderzoek/onderzoek/biobanking).

**CONTACT INFORMATION**

|  |  |
| --- | --- |
|  | **Radboudumc PI** |
| **Institution**  | Radboudumc |
| **Name**  |  |
| **Address** |  |
| **Postal code** |  |
| **City** |  |
| **Country** |  |
| **Phone number** |  |
| **Email address**  |  |

**Will any part of the planned research be performed outside of Radboudumc?**

* Not applicable
* Non-commercial partner
* Commercial partner

|  |  |
| --- | --- |
|  | **External PI** |
| **Institution**  |  |
| **Name**  |  |
| **Address** |  |
| **Postal code** |  |
| **City** |  |
| **Country** |  |
| **Phone number** |  |
| **Email address**  |  |

**Other collaborating investigators?**

|  |
| --- |
|  |

**REVIEW INFORMATION FOR CMO-LIGHT**

1. **PROPOSAL**

**1a. Title research proposal**

|  |
| --- |
|  |

**1b. Rationale plus aim of the proposal**

|  |
| --- |
|  |

**1c. Research question**

|  |
| --- |
|  |

**1d. Sample size and justification**

(Is the application been reviewed by a scientific review committee: enclose copy of letter of approval)

|  |
| --- |
|  |

**1e. Were the participants minor and/or incompetent at time of inclusion?** (If yes, elaborate)

|  |
| --- |
|  |

**1f. Study design**

|  |
| --- |
|  |

**1g. Study population, In- and exclusion criteria**

|  |
| --- |
|  |

**1h. Primary and secondary outcome measures**

|  |
| --- |
|  |

1. **BIOMATERIAL**

**2a. Request concerns the following sub-biobank**

|  |
| --- |
|  |

**2b. Type of biomaterial**

|  |
| --- |
|  |

**2c. Quantity of biomaterial per type**

|  |
| --- |
|  |

**2d. How was consent given for the use of the biomaterial?**

(Enclose the patient information and informed consent that have been used)

|  |
| --- |
|  |

**2e. Is there a risk of unsolicited findings?**

(If yes, elaborate and describe which measures have been taken to minimize the risk)

|  |
| --- |
|  |

**2f. Do you intend to use specimens for commercial purposes?** (If yes, elaborate)

|  |
| --- |
|  |

1. **DATA**

**3a. Is clinical data required for the proposal?**

|  |
| --- |
|  |

**3b. How was consent given for the use of the clinical data?**

(Enclose the patient information and informed consent that have been used)

|  |
| --- |
|  |

**3c. How is the clinical data collected and stored?**

|  |
| --- |
|  |

**3d. Is there a risk that the privacy of the participants cannot be guaranteed?** (If yes, elaborate)

|  |
| --- |
|  |